Semaglutide studies: 1,194 papers with results
Page 15 of 24
- Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS · Diabetes care · 2024
Observational study · 6 results
- A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.
le Roux CW · Diabetes, obesity & metabolism · 2026
Observational study · 6 results
- Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World Study.
Xie Z · Obesity (Silver Spring, Md.) · 2026
Observational study · 11 results
- Potential protective role of GLP-1 receptor agonists for lithium-induced nephrotoxicity: a population-based observational study.
McIntyre RS · CNS spectrums · 2025
Observational study · 3 results
- Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.
Derington CG · JAMA network open · 2025
Observational study · 37 results
- Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVD.
Tan X · Diabetes research and clinical practice · 2025
Observational study · 5 results
- Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.
Ruggiero R · European journal of pharmacology · 2025
Observational study · 25 results
- Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
Kimura T · Journal of diabetes research · 2024
Observational study · 8 results
- Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.
Kwan ATH · Clinical nutrition (Edinburgh, Scotland) · 2026
Observational study · 3 results
- Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.
Seijas-Amigo J · International journal of clinical pharmacy · 2026
Observational study · 8 results
- Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVD.
Tan X · Current medical research and opinion · 2025
Observational study · 9 results
- Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.
Eldesouki MH · United European gastroenterology journal · 2026
Observational study · 24 results
- Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
Laroche ML · European journal of clinical pharmacology · 2026
Observational study · 8 results
- Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?
Alpert Z · The Journal of arthroplasty · 2026
Observational study · 5 results
- Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis.
Ness A · Helicobacter · 2025
Observational study · 7 results
- Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.
Khare S · Advances in therapy · 2025
Observational study · 6 results
- Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.
Zhang T · The international journal of lower extremity wounds · 2026
Observational study · 9 results
- Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions.
Elgindi D · Clinics in dermatology · 2026
Observational study · 8 results
- Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.
Hwang I · Drug design, development and therapy · 2026
Observational study · 9 results
- Drug-induced gastric motility disorders: A disproportionality analysis from the FAERS and CVARD databases.
Qian Z · PloS one · 2026
Observational study · 4 results
- Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study.
Cai CX · Ophthalmology · 2026
Observational study · 8 results
- Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.
Anatriello A · Pharmacological reports : PR · 2026
Observational study · 6 results
- Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.
Pineda-Wieselberg RJ · Nutrients · 2026
Observational study · 9 results
- Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.
Chen SC · American journal of therapeutics · 2026
Observational study · 16 results
- Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.
Lin S · Andrology · 2026
Observational study · 4 results
- Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.
Arora P · Expert review of pharmacoeconomics & outcomes research · 2026
Observational study · 7 results
- Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.
Arora P · Expert review of pharmacoeconomics & outcomes research · 2025
Observational study · 6 results
- Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.
Popoviciu MS · Biomedicines · 2025
Observational study · 9 results
- Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.
Kumar S · Digestive diseases and sciences · 2025
Observational study · 7 results
- Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.
Pardo Lozano F · Endocrinologia, diabetes y nutricion · 2025
Observational study · 11 results
- Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.
Oya J · Journal of diabetes investigation · 2025
Observational study · 11 results
- Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
Wong K · Case reports in women's health · 2026
Case report or series · 5 results
- Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.
Richards JR · The Journal of clinical psychiatry · 2023
Case report or series · 2 results
- Outcomes of Semaglutide Use in Achieving Target Body Mass Index Before Renal Transplant in Five End-Stage Renal Disease Patients: A Case Series.
Al-Saad N · Cureus · 2024
Case report or series · 4 results
- Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.
Ahmadi H · BMC ophthalmology · 2025
Case report or series · 2 results
- Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma.
Gjersdal E · Pituitary · 2024
Case report or series · 12 results
- Allodynia (skin tenderness) associated with semaglutide: A case series.
Stark J · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2025
Case report or series · 4 results
- Hot Water Eliminates the Bitter Taste of Oral Semaglutide: A Report of Four Cases.
Okada S · Internal medicine (Tokyo, Japan) · 2024
Case report or series · 2 results
- Administration errors of compounded semaglutide reported to a poison control center-Case series.
Lambson JE · Journal of the American Pharmacists Association : JAPhA · 2023
Case report or series · 8 results
- Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors.
Wiener BG · Clinical toxicology (Philadelphia, Pa.) · 2024
Case report or series · 2 results
- Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis.
De la Flor JC · Case reports in nephrology and dialysis · 2022
Case report or series · 5 results
- Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.
Cirnigliaro CM · The journal of spinal cord medicine · 2024
Case report or series · 6 results
- Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.
Cymbal M · ACG case reports journal · 2025
Case report or series · 5 results
- Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.
Koceva A · Frontiers in endocrinology · 2024
Case report or series · 4 results
- "Ozempic Limb": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals With Lower Limb Amputation.
Bykowski J · American journal of physical medicine & rehabilitation · 2026
Case report or series · 4 results
- Acute Kidney Injury Associated With Semaglutide.
Leehey DJ · Kidney medicine · 2021
Case report or series · 3 results
- Case Report: Semaglutide-associated depression: a report of two cases.
Li JR · Frontiers in psychiatry · 2023
Case report or series · 3 results
- Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss.
Avraham SA · Anaesthesia reports · 2024
Case report or series · 1 result
- Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports.
Ouellette S · Journal of drugs in dermatology : JDD · 2023
Case report or series · 3 results
- Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease.
Wallace R · Nephrology (Carlton, Vic.) · 2024
Case report or series · 1 result